Male Breast Cancer: Understanding the Biology for Improved Patient Care

Retrospective part (closed to patients registration): * Men with histologically proven invasive breast carcinoma diagnosed since 1990 to 2010. * A FFPE tissue sample from the primary tumor (e.g. biopsy or surgery) is mandatory Prospective part: * All men, with histologically proven invasive breast cancer, newly presenting at the center irrespective of the stage of disease, initial diagnosis date or treatment received. * patients cannot be registered in both the retrospective and protective parts of the study * patients who newly present at the center in the 3 months prior to center activation are still eligible as long as they were not previously included in the retrospective part of the study * Before patient registration, written informed consent must be obtained according to ICH/GCP, and national/local regulations. * Collection of left-over FFPE and frozen tumor samples as well as blood is optional. Both parts: * Concomitant DCIS or LCIS are allowed only if invasive cancer is present. * Patients should be 18 years or over at the time of diagnosis. * The study will accept all stages of disease (e.g. early BC, locally advanced and metastatic disease) independent of the treatment received. Patients with past or concurrent other malignancies are eligible.